Kirchhelle A, Frühwein N, Tobüren D
Institut für Immun-, Tropenmedizin, Impfwesen, München.
Fortschr Med. 1996 Apr 20;114(11):136-40.
The efficacy and tolerability of Saccharomyces boulardii (S.b.) were investigated in patients with diarrhea contracted while travelling abroad.
The efficacy of S.b. was determined on the basis of the frequency and consistency of stools (fewer than 3 unformed stools a day), and symptom changes. A total of 95 patients (49 females, 46 males) aged between 19 and 69 (mean age 32) years were treated with S.b. at a daily dose of between 150 and 450 mg (mean 428 mg) (3 x 1-3 capsules).
Prior to admission to the study, diarrhea had persisted for an average of 11 days; under treatment with S.b. it cleared up after a mean of 5 days. A tendency towards greater efficacy in patients returning from The Middle East and South America was noted. Tolerability was assessed to be very good or good by almost all participants, with side effects occurring in only 2 cases.
The study demonstrates that S.b. is both effective and well tolerated when used for the treatment of persistent diarrhea (mean duration 11 days) that had often failed (67% of the cases) to respond to previous antidiarrheal or antibiotic drugs.
研究布拉酵母菌（S.b.）对在国外旅行期间患腹泻患者的疗效及耐受性。
根据大便频率和性状（每天少于3次不成形大便）及症状变化来确定S.b.的疗效。共有95例患者（49例女性，46例男性）接受S.b.治疗，年龄在19至69岁之间（平均年龄32岁），日剂量为150至450毫克（平均428毫克）（3×1 - 3粒胶囊）。
在进入本研究之前，腹泻平均持续了11天；接受S.b.治疗后，平均5天腹泻症状消失。研究发现从中东和南美洲回国的患者疗效更佳。几乎所有参与者对耐受性的评估都为非常好或良好，仅2例出现副作用。
该研究表明，S.b.用于治疗持续腹泻（平均病程11天）有效且耐受性良好，这类腹泻此前使用止泻药或抗生素治疗往往无效（67%的病例）。
